CLINICAL PATHWAYS / PEDIATRICS
UTI, one connected path.
One case. Follow each decision. Your answers carry forward.
For clinician education. Confirm findings, local protocols and follow-up. This tool does not replace clinical assessment. Answers stay in this open page only; refreshing or starting a new case clears them.
Who this covers & important exceptions
Based on the supplied 2026 AAP UTI guideline, for children 8 days to under 5 years. Ill-appearing children, suspected sepsis, known congenital kidney/urinary tract anomalies, neurogenic bladder, immune compromise, extreme prematurity, major congenital anomalies or major multisystem illness require individualized care. VUR-specific prevention is considered separately. Communication or neurodevelopmental differences alone are not exclusions.
Febrile infants 8–60 days with temperature ≥38°C need the complete febrile-infant evaluation. This UTI tool cannot determine discharge or exclude invasive infection. Calendar-month and day boundaries differ: a child just reaching 2 months may still be ≤60 days.
Unknown findings are never assumed normal. UA/culture thresholds guide a clinical assessment; this tool does not estimate a UTI risk percentage or calculate drug doses. If urinary symptoms cannot be reported, consider the younger-child diagnostic approach.
Evidence, thresholds & source notes
Based on Alverson BK et al. Clinical Practice Guideline for the Diagnosis and Treatment of Urinary Tract Infection in Children From 8 Days to 5 Years of Age. Pediatrics. 2026;158(4):e2026078565.
Read the AAP guideline ↗ · AAP algorithms ↗
Two UA thresholds, two different decisions
| Age | Culture screen / inflammation with culture | Presumptive-treatment anchor |
|---|---|---|
| Under 2 months | ≥5 WBC/hpf OR ≥trace LE | ≥5 WBC/hpf OR ≥trace LE |
| 2 months and older | ≥5 WBC/hpf OR ≥1+ LE | ≥10 WBC/hpf OR ≥2+ LE |
Source: Table 1, p. 5; Figures 1–3, pp. 27–29. Culture anchors: ≥10,000 CFU/mL of a single uropathogen for catheter/SPA; ≥100,000 for clean catch in older children. Under 2 months, Table 1 specifies catheter/SPA. Bag cultures cannot establish UTI. Nitrite positivity alone does not demonstrate inflammation.
How this preview handles source differences
- Duration: KAS 2 supports 3–5 days for low-risk, nonfebrile cystitis at age ≥2 years. Figure 3 simplifies treatment to 5–7 days. This tool follows the written KAS for that subgroup. For higher-risk treatment, the summary says >7 days and the detailed table gives 7–14 days; the tool presents this as individualized guidance.
- VCUG: KAS 5A and the Figure 4 decision box name circumcised males as an optional first-episode subgroup, while Figure 4’s explanatory callout says uncircumcised males. This tool follows written KAS 5A and flags the discrepancy for clinical review; neither status automatically mandates VCUG.
- Age boundaries: Table 1 uses calendar months; Figure 1 uses 8–60 days. Keep the full febrile-infant pathway active through 60 days. At 24 months, this tool uses the KAS 2 “2 years and older” duration branch.
- Clinical scope: This is a paraphrased learning aid, not an AAP product or endorsement. KAS 6 is a starting point while awaiting specialist discussion, and the guideline reports differing panel views on VUR management.
Recommendation strength
Evaluation timing and duration (KAS 1–2): conditional, low certainty. Route at 8–28 days (KAS 3A): conditional, very low certainty. Oral route after 28 days (KAS 3B): strong, very low certainty. RBUS (KAS 4): strong, low certainty. VCUG (KAS 5A–5B): conditional; high test-accuracy certainty but low overall-effect certainty. Low-risk VUR prophylaxis (KAS 6): conditional, low certainty.
Reviewed against the user-provided PDF and the official AAP listing on October 16, 2026. Drug dose calculations and a complete febrile-infant workup are outside this preview.